Genematrix Inc.

As of March 31, 2026, Genematrix Inc. carries a market capitalization of 37.93B, placing it among publicly traded companies globally. Its enterprise value stands at 26.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Genematrix Inc. has 19.96M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 3.56, and the price-to-book ratio stands at 2.20.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 26.32B versus a market cap of 37.93B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Genematrix Inc. maintains a current ratio of 4.45, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.53, indicating elevated leverage, while an interest coverage ratio of -1.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Genematrix Inc. posted a negative return on equity (ROE) of -7.11, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.64, reflecting losses generated across the asset base. The company generates approximately 156.85M in revenue per employee across its workforce of 68.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.63 indicates how many times Genematrix Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Genematrix Inc.'s stock has declined approximately 40.95% over the past 52 weeks. The 50-day moving average sits at 1,563.58, while the 200-day moving average is 1,868.96.

Over the twelve months ended March 31, 2026, Genematrix Inc. generated 10.67B in revenue and converted that into -1.27B in net income, yielding earnings per share of -63.57. EBITDA reached -186.01M, while operating income came in at -718.10M.

As of March 31, 2026, Genematrix Inc. holds 15.33B in cash and equivalents against 3.71B in total debt, resulting in a net debt position of 1.43B. Total book value stands at 17.25B, with working capital of 15.61B providing operational flexibility.

Genematrix Inc. produced 865.84M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -61.97M in capital expenditures, free cash flow totaled 803.86M - equivalent to 40.27 per share.

Over the twelve months ended March 31, 2026, Genematrix Inc. posted a gross margin of 58.63, reflecting its pricing power and cost economics. The operating margin of -6.73 and net profit margin of -11.90 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 2.12, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.16, meaning Genematrix Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genematrix Inc.'s most recent stock split took place on July 24, 2018 with a 2:3 split ratio.

As of March 31, 2026, Genematrix Inc. has an Altman Z-Score of 2.10, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.